title: Deletion Mutations Keep Kinase Inhibitors in the Loop.
abstract: Effective clinical application of conformationally selective kinase inhibitors requires tailoring drug choice to the tumor's activating mutation(s). In this issue of Cancer Cell, Foster et al. (2016) describe how activating deletions in BRAF, EGFR, and HER2 cause primary resistance to common inhibitors, suggesting strategies for improved inhibitor selection.
authors.affiliation: Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA; Cancer Biology Institute, Yale University, West Haven, CT 06516, USA.
authors.forename: Daniel M
authors.initials: DM
authors.lastname: Freed
authors.affiliation: Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA; Cancer Biology Institute, Yale University, West Haven, CT 06516, USA.
authors.forename: Jin H
authors.initials: JH
authors.lastname: Park
authors.affiliation: Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA.
authors.forename: Ravi
authors.initials: R
authors.lastname: Radhakrishnan
authors.affiliation: Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520, USA; Cancer Biology Institute, Yale University, West Haven, CT 06516, USA. Electronic address: mark.lemmon@yale.edu.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Lemmon
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D066246:ErbB Receptors / Q000235:genetics; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics; D009154:Mutation; D009369:Neoplasms / Q000235:genetics*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D017384:Sequence Deletion
chemical_list: D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors